ArticleDiabetes & metabolism journal2025
Diabetes Fact Sheets in Korea 2024.
Article in Diabetes & metabolism journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs.Diabetes & metabolism journal · 2026Trial
- Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial.Diabetes, obesity & metabolism · 2026Trial
- Efficacy and Safety of HD-6277, a Novel G Protein-Coupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical Trial.Diabetes & metabolism journal · 2026Trial
- Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial.Diabetes, obesity & metabolism · 2026 · on this mapTrial
- Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial.Diabetes, obesity & metabolism · 2025Trial
- Body roundness index shows a short-term, sex-specific advantage over body mass index in predicting incident diabetes: a longitudinal prospective cohort study.Journal of endocrinological investigation · 2026Article
- Lifestyle Combination Patterns as Key Modifiable Factors for Type 2 Diabetes Mellitus Risk among Middle-Aged Korean Men.Diabetes & metabolism journal · 2026Article
- Association between physical function and type 2 diabetes risk in older adults: a longitudinal analysis from the KoGES-Anseong cohort.European geriatric medicine · 2026Article
- Development of a nutrition program for Koreans with type 2 diabetes based on the health belief model: a pre-post intervention study.Korean journal of community nutrition · 2026Article
- Hypercortisolism in Type 2 Diabetes with Treatment-Resistant Hyperglycemia: A Treatable Metabolic Phenotype?Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Determinants of Self-Reported Unmet Healthcare Needs by Disability Status: A Secondary Cross-Sectional Analysis of Linked National Survey and Administrative Data from Korea.Healthcare (Basel, Switzerland) · 2026Article
- Associations of higher protein intake with diet quality and diabetes-related metabolic health indicators in Korean adults without diabetes: analysis of Korean National Health and Nutrition Examination Survey (KNHANES) 2019-2021.Nutrition research and practice · 2026Article
- Development and temporal external validation of a high-specificity XGBoost rule-in model for diabetes in middle-aged and older Korean adults.Diabetology & metabolic syndrome · 2026Article
- Association Between Remnant Cholesterol and Muscle Mass and Quality: Insights from Muscle Quality Mapping and Abdominal Computed Tomography.Diagnostics (Basel, Switzerland) · 2026Article
- Utilization of glycated hemoglobin testing in the Korean health check-up population from local clinics and hospitals and its impact on diabetes and prediabetes classification.BMC endocrine disorders · 2026Article
- Ten-year healthcare utilization patterns among patients with type 2 diabetes and degenerative spinal disorders: a nationwide comparative analysis using nationwide sample.BMC health services research · 2026Article
- Physical activity levels and HINT-8 health-related quality of life in Korean adults with diabetes: analysis of KNHANES 2019-2021.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Association between relative handgrip strength and glycemic control among male automobile manufacturing workers using vibration tools in South Korea.Annals of occupational and environmental medicine · 2026Article
- Associations of psychological insulin resistance, diabetes-related stress, and intention to use complementary and alternative diets with self-management among older adults with type 2 diabetes: A cross-sectional study.Journal of Korean gerontological nursing · 2026Article
- Factors associated with glycemic control in Korean older adults with diabetes living alone: A secondary analysis.Journal of Korean gerontological nursing · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
backgruoundThis study aimed to investigate the prevalence, management, and comorbidities of diabetes mellitus among Korean adults.
methodsData from the Korea National Health and Nutrition Examination Survey (2019-2022) were analyzed to assess the prevalence, treatment, risk factors, and comorbidities of diabetes. Comparisons between young and older adults with diabetes were emphasized.
resultsAmong Korean adults aged ≥30 years, the prevalence of diabetes is 15.5% during 2021-2022. Of these, 74.7% were aware of their condition, 70.9% received antidiabetic treatment, and only 32.4% achieved glycosylated hemoglobin (HbA1c) <6.5%. Moreover, 15.9% met the integrated management targets, which included HbA1c <6.5%, blood pressure <140/85 mm Hg, and low-density lipoprotein cholesterol <100 mg/dL. In young adults aged 19 to 39 years, the prevalence of diabetes was 2.2%. Among them, 43.3% were aware of their condition, 34.6% received treatment, and 29.6% achieved HbA1c <6.5%. Obesity affected 87.1%, and 26.9% had both hypertension and hypercholesterolemia. Among adults aged ≥65 years, the prevalence of diabetes was 29.3%, with awareness, treatment, and control rates of 78.8%, 75.7%, and 31.2%, respectively. Integrated management targets (HbA1c <7.5%, hypertension, and lipids) were achieved by 40.1%.
conclusionDiabetes mellitus remains highly prevalent among Korean adults, with significant gaps in integrated glycemic, blood pressure, and lipid control. Older adults with diabetes show higher awareness and treatment rates but limited integrated management outcomes. Young adults with diabetes bear a significant burden of obesity and comorbidities, alongside low awareness and treatment rates. Therefore, early intervention programs, education, and strategies tailored to younger populations are urgently required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.